Cointime

AlgoTherapeutix

company

About

AlgoTherapeutix is the operator of a biotechnology company designed to develop topical treatments for complex pain.

  • Suresnes,Ile-de-France,France
  • 1 - 10

Highlights

Total Funding Amount
€22.60M $12M
Funding Rounds
3
Investors
2
Employee Profiles
5

Details

Last Funding Type
Series B
Last Funding Money Raised
€20M
Industries
Biotechnology,Information Technology,Pharmaceutical
Founded date
Jan 1, 2018
Number Of Employee
1 - 10
Operating Status
Active
Also Known As
AlgoTx

AlgoTx creates solutions to help patients suffering from difficult-to-treat conditions. The organization accomplishes this by emphasizing conditions with no proven or licensed therapy and adapting treatment to the very particular needs of the people afflicted. ATX01's admission into Phase 2 in Chemotherapy-Induced Peripheral Neuropathy has been approved by the FDA. In the meanwhile, AlgoTx is investigating its potential in erythromelalgia, a rare and painful condition.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
€22.60M $12M
AlgoTherapeutix has raised a total of €22.60M $12M in funding over 2 rounds. Their latest funding was raised on Jan 14, 2022 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jan 14, 2022 Series B €20M — — — Detail
Nov 24, 2020 Series A $12M 2 Bpifrance — Detail
Nov 20, 2019 Seed €2.60M 1 — — Detail

Investors

Number of Lead Investors
Number of Investors
1
2
AlgoTherapeutix is funded by 2 investors. Bpifrance and Omnes Capital are the most recent investors.
Investor Name Lead Investor Funding Round
Bpifrance Yes Series A
Omnes Capital — Series A

Employee Profiles

Number of Employee Profiles
5
AlgoTherapeutix has 5 current employee profiles, including Executive Philippe Picaut
Philippe Picaut
Executive
Stéphane Thiroloix
Board member
Olivier Bohuon
Executive
Jens Ellrich
Executive
Cointime
เนื้อหา
บริษัท